Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

HER2 ADC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Cytotoxin (2) ADC Linker (1) Drug-Linker Conjugates for ADC (4) Antibody-Drug Conjugates (ADCs) (10) EGFR (9) Microtubule/Tubulin (1) Radionuclide-Drug Conjugates (RDCs) (1) Topoisomerase (3)
By Research Areas:	Cancer (18)
Click Chemistry:	TCO (1)

Inhibitors & Agonists

Inhibitory Antibodies

Click Chemistry

Targets Recommended: ADC Cytotoxin ADC Antibody ADC Linker Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138298A

Trastuzumab deruxtecan 2 Publications Verification DS-8201; DS-8201a	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-138298

Trastuzumab deruxtecan (solution) 2 Publications Verification DS-8201 (solution); DS-8201a (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .

HY-161252

PBD-monoamide	ADC Cytotoxin	Cancer
PBD-monoamide, a modified PBD (pyrrolobenzodiazepine) dimer, is an ADC Cytotoxin. PBD-monoamide can be used for synthesis of DHES0815A (an HER2 ADC). PBD-monoamide has DNA-binding activity and reduces cell viability .

HY-160015

CB07-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of *ADCs. ADC* conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research .

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting *ADC* that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-164763

SHR-A1201	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
SHR-A1201 is a *HER2*-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a *HER2*-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-164992

Trastuzumab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Trastuzumab MMAE is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab MMAE is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab MMAE can be used for the research of HER2-positive breast cancer .

HY-168285

LE01	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .

HY-13631D

Dxd Maximum Cited Publications 9 Publications Verification Exatecan derivative for ADC	Topoisomerase ADC Cytotoxin	Cancer
Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC₅₀ of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

HY-154802

TCO-GK-PEG4-NHS ester	ADC Linker Radionuclide-Drug Conjugates (RDCs)	Cancer
TCO-GK-PEG4-NHS ester is an ADC Linker, and can be used for synthesis of ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d. ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d binds with high affinity and immunoreactivity to *HER2* . TCO-GK-PEG4-NHS ester is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

HY-148067

XMT-1519 conjugate-1	Drug-Linker Conjugates for ADC	Cancer
ΧΜΤ-1519 conjugate-1 (compound 31) is a linker for the HER-2 monoclonal antibody XMT-1519, which can be used to synthesize ADC and increase anti-tumor activity .

HY-P9921

Trastuzumab emtansine 2 Publications Verification Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting *HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)*) .

HY-164202

ORM-5029	Antibody-Drug Conjugates (ADCs)	Cancer
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer .

HY-P9985

Disitamab vedotin 1 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate *(ADC)* comprising a monoclonal antibody against human epidermal growth factor receptor 2 *(HER2)* conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a *HER2*-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99547

Trastuzumab duocarmazine (vic)-Trastuzumab duocarmazine	Antibody-Drug Conjugates (ADCs)	Cancer
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting *ADC* that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting *HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)*) .

Cat. No.	Product Name		Classification

HY-154802

TCO-GK-PEG4-NHS ester		TCO
TCO-GK-PEG4-NHS ester is an ADC Linker, and can be used for synthesis of ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d. ^[18F]AlF-NOTA-Tz-TCO-GK-2Rs15d binds with high affinity and immunoreactivity to *HER2* . TCO-GK-PEG4-NHS ester is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.